Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 564057, 10 pages
http://dx.doi.org/10.1155/2015/564057
Research Article

Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma

1Department of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
2Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
3Institute of Digestive Disease, Partner State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong
4Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong
5Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong
6Li Ka Shing Institute of Health Science, Sir Y. K. Pao Cancer Centre, The Chinese University of Hong Kong, Shatin, Hong Kong

Received 5 January 2015; Revised 27 January 2015; Accepted 27 January 2015

Academic Editor: Stamatios Theocharis

Copyright © 2015 Anthony W. H. Chan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, M. Ervik et al., “Cancer incidence and mortality worldwide: IARC cancer base,” GLOBOCAN 2012 v1.0 11, 2014, http://globocan.iarc.fr. View at Google Scholar
  2. C.-L. Chen, C. S. Kabiling, and A. M. Concejero, “Why does living donor liver transplantation flourish in Asia?” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 12, pp. 746–751, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 4, pp. 908–943, 2012. View at Publisher · View at Google Scholar
  4. G. Torzilli, J. Belghiti, N. Kokudo et al., “A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group,” Annals of Surgery, vol. 257, no. 5, pp. 929–937, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. H. Chun, S. U. Kim, J. Y. Park et al., “Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma,” European Journal of Cancer, vol. 47, no. 17, pp. 2568–2575, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. The Cancer of the Liver Italian Program (CLIP) Investigators, “A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients,” Hepatology, vol. 28, no. 3, pp. 751–755, 1998. View at Google Scholar · View at Scopus
  7. S. L. Chan, P. J. Johnson, F. Mo et al., “International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study,” Chinese Journal of Cancer, vol. 33, no. 10, pp. 481–491, 2014. View at Google Scholar
  8. M. Kudo, H. Chung, S. Haji et al., “Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score,” Hepatology, vol. 40, no. 6, pp. 1396–1405, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. L. Chan, F. K. F. Mo, P. J. Johnson et al., “New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy,” Journal of Clinical Oncology, vol. 27, no. 3, pp. 446–452, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. S. Kamath, R. H. Wiesner, M. Malinchoc et al., “A model to predict survival in patients with end-stage liver disease,” Hepatology, vol. 33, no. 2, pp. 464–470, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. S. L. Chan, F. K. F. Mo, P. J. Johnson et al., “Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population,” Journal of Gastroenterology and Hepatology, vol. 26, no. 2, pp. 340–347, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Ueno, G. Tanabe, K. Sako et al., “Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients,” Hepatology, vol. 34, no. 3, pp. 529–534, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-N. Vauthey, D. Ribero, E. K. Abdalla et al., “Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment,” Journal of the American College of Surgeons, vol. 204, no. 5, pp. 1016–1027, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Munene, J.-N. Vauthey, and E. Dixon, “Summary of the 2010 AHPBA/SSO/SSAT consensus conference on HCC,” International Journal of Hepatology, vol. 2011, Article ID 565060, 4 pages, 2011. View at Publisher · View at Google Scholar
  15. F.-D. Huitzil-Melendez, M. Capanu, E. M. O'Reilly et al., “Advanced hepatocellular carcinoma: which staging systems best predict prognosis?” Journal of Clinical Oncology, vol. 28, no. 17, pp. 2889–2895, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Y.-Y. Shao, L.-C. Lu, Z.-Z. Lin et al., “Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems,” British Journal of Cancer, vol. 107, no. 10, pp. 1672–1677, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Maida, E. Orlando, C. Cammà, and G. Cabibbo, “Staging systems of hepatocellular carcinoma: a review of literature,” World Journal of Gastroenterology, vol. 20, no. 15, pp. 4141–4150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. D. H. Esper and W. A. Harb, “The cancer cachexia syndrome: a review of metabolic and clinical manifestations,” Nutrition in Clinical Practice, vol. 20, no. 4, pp. 369–376, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M.-C. Yu, K.-M. Chan, C.-F. Lee et al., “Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence?” Journal of Gastrointestinal Surgery, vol. 15, no. 8, pp. 1440–1449, 2011. View at Publisher · View at Google Scholar · View at Scopus